Do analysts recommend ABVC or INDP?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Indaptus Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ABVC or INDP more profitable?

ABVC BioPharma's return on equity of -62.46% beat Indaptus Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% Indaptus Therapeutics N/A -1,030.07% -299.69%

Does the media favor ABVC or INDP?

In the previous week, Indaptus Therapeutics had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Indaptus Therapeutics and 1 mentions for ABVC BioPharma. Indaptus Therapeutics' average media sentiment score of 0.80 beat ABVC BioPharma's score of 0.75 indicating that Indaptus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Indaptus Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate CRDL or ABVC?

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 683.41%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CRDL or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cardiol Therapeutics N/A -229.43% -165.60% ABVC BioPharma N/A -62.46% -39.99%

Do analysts recommend GNLX or ABVC?

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 510.38%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GNLX or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% ABVC BioPharma N/A -62.46% -39.99%

Does the media refer more to GNLX or ABVC?

In the previous week, Genelux had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Genelux and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.75 beat Genelux's score of -0.05 indicating that ABVC BioPharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer SPRB or ABVC?

Spruce Biosciences currently has a consensus price target of $169.67, indicating a potential upside of 244.36%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SPRB or ABVC more profitable?

ABVC BioPharma's return on equity of -62.46% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Spruce Biosciences N/A -155.40% -101.67% ABVC BioPharma N/A -62.46% -39.99%

Does the media refer more to SPRB or ABVC?

In the previous week, Spruce Biosciences had 6 more articles in the media than ABVC BioPharma. MarketBeat recorded 7 mentions for Spruce Biosciences and 1 mentions for ABVC BioPharma. Spruce Biosciences' average media sentiment score of 0.87 beat ABVC BioPharma's score of 0.75 indicating that Spruce Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spruce Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate ABVC or VTVT?

vTv Therapeutics has a consensus price target of $53.00, suggesting a potential upside of 65.33%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 vTv Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Is ABVC or VTVT more profitable?

vTv Therapeutics' return on equity of 3.96% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -62.46% -39.99% vTv Therapeutics N/A 3.96% 2.86%

Does the media prefer ABVC or VTVT?

In the previous week, vTv Therapeutics had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.75 beat vTv Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive vTv Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ABVC BioPharma (ABVC) Competitors

$1.33 -0.01 (-0.75%)

As of 11:10 AM Eastern

Compare

ABVC vs. INDP, CRDL, GNLX, SPRB, and VTVT

Should you buy ABVC BioPharma stock or one of its competitors? MarketBeat compares ABVC BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ABVC BioPharma include Indaptus Therapeutics (INDP), Cardiol Therapeutics (CRDL), Genelux (GNLX), Spruce Biosciences (SPRB), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry.

How does ABVC BioPharma compare to Indaptus Therapeutics?

ABVC BioPharma (NASDAQ:ABVC) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Indaptus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

11.4% of ABVC BioPharma shares are owned by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are owned by institutional investors. 19.0% of ABVC BioPharma shares are owned by insiders. Comparatively, 23.6% of Indaptus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

ABVC BioPharma has higher revenue and earnings than Indaptus Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Indaptus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	67.80	-$7.91M	-$0.40	N/A
Indaptus Therapeutics	N/A	N/A	-$20.85M	-$15.40	N/A

ABVC BioPharma's return on equity of -62.46% beat Indaptus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
Indaptus Therapeutics	N/A	-1,030.07%	-299.69%

In the previous week, Indaptus Therapeutics had 3 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Indaptus Therapeutics and 1 mentions for ABVC BioPharma. Indaptus Therapeutics' average media sentiment score of 0.80 beat ABVC BioPharma's score of 0.75 indicating that Indaptus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Indaptus Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ABVC BioPharma has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market. Comparatively, Indaptus Therapeutics has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Summary

ABVC BioPharma beats Indaptus Therapeutics on 6 of the 11 factors compared between the two stocks.

How does ABVC BioPharma compare to Cardiol Therapeutics?

Cardiol Therapeutics (NASDAQ:CRDL) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

In the previous week, ABVC BioPharma had 1 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 1 mentions for ABVC BioPharma and 0 mentions for Cardiol Therapeutics. ABVC BioPharma's average media sentiment score of 0.75 beat Cardiol Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
ABVC BioPharma	Positive

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 683.41%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ABVC BioPharma has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
ABVC BioPharma	$510K	67.80	-$7.91M	-$0.40	N/A

Cardiol Therapeutics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ABVC BioPharma's return on equity of -62.46% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
ABVC BioPharma	N/A	-62.46%	-39.99%

Summary

ABVC BioPharma beats Cardiol Therapeutics on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Genelux?

Genelux (NASDAQ:GNLX) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

ABVC BioPharma's return on equity of -62.46% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
ABVC BioPharma	N/A	-62.46%	-39.99%

37.3% of Genelux shares are owned by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 19.0% of ABVC BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Genelux has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

ABVC BioPharma has higher revenue and earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$8K	16,529.15	-$32.15M	-$0.85	N/A
ABVC BioPharma	$510K	67.80	-$7.91M	-$0.40	N/A

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 510.38%. Given Genelux's stronger consensus rating and higher probable upside, analysts clearly believe Genelux is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Genelux had 2 more articles in the media than ABVC BioPharma. MarketBeat recorded 3 mentions for Genelux and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.75 beat Genelux's score of -0.05 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genelux	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ABVC BioPharma beats Genelux on 8 of the 14 factors compared between the two stocks.

How does ABVC BioPharma compare to Spruce Biosciences?

Spruce Biosciences (NASDAQ:SPRB) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

ABVC BioPharma has lower revenue, but higher earnings than Spruce Biosciences. ABVC BioPharma is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spruce Biosciences	$4.91M	27.60	-$38.97M	-$36.60	N/A
ABVC BioPharma	$510K	67.80	-$7.91M	-$0.40	N/A

91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 4.3% of Spruce Biosciences shares are held by company insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Spruce Biosciences currently has a consensus price target of $169.67, indicating a potential upside of 244.36%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Spruce Biosciences is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spruce Biosciences	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Spruce Biosciences has a beta of 3.12, suggesting that its share price is 212% more volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market.

In the previous week, Spruce Biosciences had 6 more articles in the media than ABVC BioPharma. MarketBeat recorded 7 mentions for Spruce Biosciences and 1 mentions for ABVC BioPharma. Spruce Biosciences' average media sentiment score of 0.87 beat ABVC BioPharma's score of 0.75 indicating that Spruce Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spruce Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ABVC BioPharma's return on equity of -62.46% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	-155.40%	-101.67%
ABVC BioPharma	N/A	-62.46%	-39.99%

Summary

Spruce Biosciences beats ABVC BioPharma on 9 of the 15 factors compared between the two stocks.

How does ABVC BioPharma compare to vTv Therapeutics?

ABVC BioPharma (NASDAQ:ABVC) and vTv Therapeutics (NASDAQ:VTVT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, vTv Therapeutics had 1 more articles in the media than ABVC BioPharma. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 0.75 beat vTv Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
vTv Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

vTv Therapeutics' return on equity of 3.96% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-62.46%	-39.99%
vTv Therapeutics	N/A	3.96%	2.86%

ABVC BioPharma has higher earnings, but lower revenue than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than ABVC BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	67.80	-$7.91M	-$0.40	N/A
vTv Therapeutics	$1.02M	123.83	-$26.97M	-$0.93	N/A

vTv Therapeutics has a consensus price target of $53.00, suggesting a potential upside of 65.33%. Given vTv Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe vTv Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
vTv Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 17.5% of vTv Therapeutics shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 6.0% of vTv Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ABVC BioPharma has a beta of 0.56, suggesting that its share price is 44% less volatile than the broader market. Comparatively, vTv Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

Summary

vTv Therapeutics beats ABVC BioPharma on 10 of the 16 factors compared between the two stocks.

Get ABVC BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVC vs. The Competition

Export

Metric	ABVC BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$34.58M	$3.31B	$6.46B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.58%
P/E Ratio	-3.32	19.05	23.94	23.78
Price / Sales	67.80	305.18	531.66	117.30
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	2.56	8.09	10.55	6.76
Net Income	-$7.91M	$23.89M	$3.56B	$337.14M
7 Day Performance	6.40%	-3.06%	-0.93%	-1.75%
1 Month Performance	25.47%	2.84%	1.58%	2.32%
1 Year Performance	-17.90%	36.43%	20.99%	25.63%

ABVC BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVC ABVC BioPharma	0.7766 of 5 stars	$1.33 -0.7%	N/A	-13.0%	$34.58M	$510K	N/A	30	Gap Up
INDP Indaptus Therapeutics	1.2765 of 5 stars	$1.27 +14.4%	N/A	-78.2%	$143.82M	N/A	N/A	6	Gap Up
CRDL Cardiol Therapeutics	1.7881 of 5 stars	$1.28 -1.5%	$8.50 +564.1%	-23.4%	$143.13M	N/A	N/A	20
GNLX Genelux	2.3377 of 5 stars	$3.06 +1.7%	$18.00 +488.2%	+14.5%	$137.21M	$10K	N/A	10
SPRB Spruce Biosciences	2.986 of 5 stars	$49.52 -4.4%	$186.60 +276.8%	+929.1%	$136.28M	N/A	N/A	20	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVC) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ABVC BioPharma (ABVC) Competitors

ABVC vs. INDP, CRDL, GNLX, SPRB, and VTVT

How does ABVC BioPharma compare to Indaptus Therapeutics?

Summary

How does ABVC BioPharma compare to Cardiol Therapeutics?

Summary

How does ABVC BioPharma compare to Genelux?

Summary

How does ABVC BioPharma compare to Spruce Biosciences?

Summary

How does ABVC BioPharma compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ABVC BioPharma (ABVC) Competitors

ABVC vs. INDP, CRDL, GNLX, SPRB, and VTVT

How does ABVC BioPharma compare to Indaptus Therapeutics?

Do analysts recommend ABVC or INDP?

Do institutionals and insiders have more ownership in ABVC or INDP?

Which has stronger earnings & valuation, ABVC or INDP?

Is ABVC or INDP more profitable?

Does the media favor ABVC or INDP?

Which has more risk & volatility, ABVC or INDP?

Summary

How does ABVC BioPharma compare to Cardiol Therapeutics?

Does the media refer more to CRDL or ABVC?

Do analysts rate CRDL or ABVC?

Which has better earnings and valuation, CRDL or ABVC?

Which has more risk and volatility, CRDL or ABVC?

Do insiders and institutionals hold more shares of CRDL or ABVC?

Is CRDL or ABVC more profitable?

Summary

How does ABVC BioPharma compare to Genelux?

Is GNLX or ABVC more profitable?

Do insiders & institutionals have more ownership in GNLX or ABVC?

Which has more risk and volatility, GNLX or ABVC?

Which has better earnings & valuation, GNLX or ABVC?

Do analysts recommend GNLX or ABVC?

Does the media refer more to GNLX or ABVC?

Summary

How does ABVC BioPharma compare to Spruce Biosciences?

Which has higher earnings and valuation, SPRB or ABVC?

Do institutionals and insiders believe in SPRB or ABVC?

Do analysts prefer SPRB or ABVC?

Which has more volatility and risk, SPRB or ABVC?

Does the media refer more to SPRB or ABVC?

Is SPRB or ABVC more profitable?

Summary

How does ABVC BioPharma compare to vTv Therapeutics?

Does the media prefer ABVC or VTVT?

Is ABVC or VTVT more profitable?

Which has better valuation & earnings, ABVC or VTVT?

Do analysts rate ABVC or VTVT?

Do institutionals & insiders hold more shares of ABVC or VTVT?

Which has more volatility and risk, ABVC or VTVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVC vs. The Competition

ABVC BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools